

28th November 2014



ABN: 56 006 569 106

A: 108 Outram Street
West Perth, WA 6005

T: +61 (8) 9486 2333
F: +61 (8) 9355 4580

The ASX Market Announcements Platform
ASX Limited
By E-lodgement

ASX Announcement

RESULTS OF 2013 ANNUAL GENERAL MEETING

Pursuant to ASX listing rule 3.13.2 and section 251AA of the Corporations Act, the Company advises that the Resolution 1 contained in the Notice of Annual General Meeting dated 20 October 2014 was carried today at the meeting of shareholders on a show of hands and Resolution 2 was withdrawn as a consequence of the Remuneration Report being approved at both the 2012 Annual General Meeting (held earlier today) and this 2013 Annual General Meeting.

The proxy votes in respect of each resolution were:

Resolution	For	Against	Abstain	Discretionary
1	42,443,847	-	25,000,000	20,040,301
2	30,136,466	12,304,931	25,000,000	20,040,301

Yours faithfully

Sean Henbury

Company Secretary

For further information contact:

Mr. Rudi Michelson

Monsoon Communications

Ph: +61 (0) 3 9620 3333

Dr. Robert Crombie

Managing Director

Ph: +61 (0) 3 9982 4563

About Virax

Virax is a clinical stage oncology company currently engaged in the development of novel products for the treatment of cancer. It holds an exclusive worldwide license to the novel cancer compound GGTI-2418 for the treatment of multiple myeloma, breast and pancreatic cancer.

GGTI-2418 is expected to enter Phase 1b/2 clinical trials in breast cancer and myeloma in early 2015.

Virax owns the US oncology company AKTivate and its novel TCN-P cancer drug. The company's technology inhibits the highly promising drug target AKT and includes two active clinical trials – a Phase 1b/2 in breast cancer and an active Phase 1b in ovarian cancer. These trials are funded by US government authorities, including grants from the Department of Defence and National Cancer Institute.

In addition, the company has granted a license to major French biotechnology company Transgene for access to its Co-X-Gene™ technology for use in two of Transgene's immunotherapeutic products.